Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01034085 · ClinicalTrials.gov registry record

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
62
Enrollment target

NCT01034085: Completed study, sponsored by National Institute on Drug Abuse (NIDA).

NCT01034085 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01034085 has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
62 participants
Enrollment target

Study Summary

Background: * Some people with schizophrenia have problems with their working memory and paying attention for extended periods. These difficulties cannot be treated with antipsychotic medications or with many standard therapies. * The prevalence of cigarette smoking among individuals with schizophrenia is about three times higher than in the general population. Research has shown that nicotine, the addictive component found in cigarettes, can help improve attentional and working memory performance. Researchers are interested in learning more about whether there may be an overlap in the cognitive functions beneficially affected by nicotine and areas of dysfunction in individuals with schizophrenia. Objectives: * To evaluate the potential of transdermal nicotine to alleviate cognitive deficits in schizophrenia, and to determine whether naturally maintained cigarette-smoking, in comparison, is an effective self-medication. * To gather preliminary data on genetics that may account for individual and group differences in the performance effects of nicotine. Eligibility: \- Current smokers (25 or more cigarettes per week for at least 1 year) between 18 and 55 years of age who are either healthy volunteers or have been diagnosed with schizophrenia/schizoaffective disorder. Design: * The study will require five visits to the research center, with an initial screening visit, a training session, and three test sessions. Ideally, all visits will occur 1 week apart. * Training session: Participants will receive training on the types of computerized cognitive and attentional behavior tests that will be given during the active portion of the study. Participants will also fill out questionnaires on nicotine use and other alcohol and drug use. * Test sessions: Participants will be assigned to random groups and will complete tests that assess cognitive performance (a) while maintaining their usual smoking behavior, (b) after minimal deprivation (3.5 hours without smoking) whi

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2009-06-02
Est. Completion 2013-06-11

What the finished NCT01034085 record still lists

NCT01034085 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 62 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01034085 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01034085 about?

NCT01034085 is a clinical study titled "Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia". Background: * Some people with schizophrenia have problems with their working memory and paying attention for extended periods. These difficulties cannot be treated with antipsychotic medications or with many standard therapies. * The prevalence of cigarette smoking among individuals with schizophr...

What is the current status of trial NCT01034085?

This trial is currently completed. The enrollment target is 62 participants. The study started on 2009-06-02. Estimated completion is 2013-06-11.

Who is sponsoring clinical trial NCT01034085?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01034085, the US trial registry maintained by the National Library of Medicine. NCT01034085 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.